Datavant has completed its acquisition of Aetion, an innovator in real-world evidence (RWE) that assists in healthcare decision-making. Aetion is now part of Datavant’s Life Sciences division.
This acquisition enables Datavant to provide a comprehensive platform for data analysis, helping healthcare and life sciences companies effectively address research questions about the clinical impact of therapies in development and on the market.
Together, Datavant and Aetion have over 300 data partners, offering insights from sources like electronic health records, claims data, specialty pharmacy, registries, imaging, lab results, and social determinants of health.
KEY QUOTES:
“This transaction represents the beginning of a promising new chapter together for two industry-leaders whose joint mission is to make real world evidence truly actionable, and we are delighted to welcome the Aetion team to Datavant.”
“We will leverage our complementary capabilities to help create a bridge between different datasets and transform the way data is being leveraged across the drug development continuum.”
Kyle Armbrester, CEO of Datavant
